Elsevier

Ultrasonics Sonochemistry

Volume 27, November 2015, Pages 682-687
Ultrasonics Sonochemistry

Ultrasound-guided high-intensity focused ultrasound treatment for uterine fibroid & adenomyosis: A single center experience from the Republic of Korea

https://doi.org/10.1016/j.ultsonch.2015.05.033Get rights and content
Under a Creative Commons license
open access

Highlights

  • A clinical study assessing the efficacy of HIFU for uterine fibroid or adenomyosis.

  • A cohort of 618 patients, of which 272 had uterine fibroid and 346 had adenomyosis.

  • Chongqing Haifu JC Focused Ultrasound (USgHIFU) Tumor Therapeutic System was used.

  • USgHIFU is an effective and safe non-invasive therapy for fibroid and adenomyosis.

Abstract

Objectives

This study aimed to assess the therapeutic outcomes of patients with uterine fibroid or adenomyosis treated by ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation at Incheon Christian Hospital, Korea.

Methods

This study included 618 patients, of which 272 suffered from uterine fibroid and 346 suffered from adenomyosis. Treatment was administrated using the Model Haifu JC Focused Ultrasound Tumor Therapeutic System (Chongqing Haifu Technology, Chongqing, China) under real-time ultrasound guidance. A follow-up was conducted on volume change as well as on symptom improvement using the Symptom Severity Score (SSS) and Uterine Fibroid Symptom and Quality of Life (UFS–QOL) after treatment.

Result

The uterine fibroid volume reduction rates (%) were 58.08%, 66.18%, and 77.59% at 3, 6, and 12 months after treatment, respectively. The SSS reduction rates (%) were 55.58%, 52.76%, and 50.39% by 3, 6, and 12 months, respectively. The UFS–QOL score increasing rates (%) were 42.66%, 43.50%, and 43.45% by 3, 6, and 12 months, respectively. The uterine volume reduction rates (%) for adenomyosis were 43.99%, 47.01%, and 53.98% by 3, 6, and 12 months, respectively. The SSS reduction rates (%) for adenomyosis were 55.61%, 52.38%, and 57.98% by 3, 6, and 12 months, respectively. The UFS–QOL score increasing rates (%) for adenomyosis UFS–QOL score were 80.06%, 69.39%, and 85.07% by 3, 6, and 12 months, respectively.

Conclusion

We conclude that USgHIFU treatment for uterine fibroid and adenomyosis is an effective non-invasive therapy via the assessment of fibroid volume reduction, symptom improvement, UFS–QOL score increase, and acceptable level of side effects. Although preliminary experience of HIFU is encouraging, well-designed prospective trials and more clinical experiences are needed to ascertain the efficacy and safety of this new treatment.

Keywords

HIFU
Uterine fibroid
Adenomyosis

Cited by (0)